CXCR4 and pancreatic neoplasm: While incorporation of AMD3100 into CAR-T cell treatment regimens has yet to be reported, use of AMD3100 to block the CXCL12-CXCR4 signaling axis was found to promote PD1 inhibition in hepatocellular carcinoma and pancreatic cancer (30, 76).